MNC pharma: Time to re-look at them without bias? 8 MNC pharma stocks, 5 with an upside potential of 15 to 52%While they still trade at premium valuations, they have not created much wealth for shareholders in recent times. The age-old theory that h...
MNC pharma: Time to relook at them? 8 pharma stocks, 4 with an upside potential of between 16 and 47%In the past four years, several MNC pharma companies announced the sale of a part of their businesses in India. Some of this was part of gl...
Why predict time and magnitude of correction, focus on business and diversification: 6 large-cap stocks with upside potential of up to 38%After a long time, probably after March 2024, stock prices and the indices have corrected in a very sharp manner – and across the board. Th...
For investors with risk appetite; 5 mid cap stocks with right RoE and upside potential of up to 25%Earning seasons not only helps in judging what is happening to individual companies but more importantly it helps gauge the undercurrent of...
For risk takers: 5 midcap stocks from different sectors with right RoE and upside potential of up to 30%When valuations are high and sentiments are bullish and earning season is very close, it would be better to add the words like portfolio re...
For risk takers; 5 midcap stocks from different sectors with right levels of RoE and upside potential of up to 32%Last week, mid-cap stocks saw a sharp correction, because there was no major follow up selling, making the overall trend stay in the bullis...
Tactical buys in time of correction? 4 MNC pharma stocks with upside potential of up to 28%In the last two decades MNC pharma companies, whose parent companies were setting up 100 percent owned subsidiaries in India and started ro...
Will they make a comeback? 4 MNC pharma stocks with upside potential of up to 28%After the IT bull of 2000, as a new set of Indian companies took the centerstage, a number of MNCs stocks lost their shine at least on the ...
Will MNC pharma stocks get back their mojo for good or is it just a blip?Most of the MNC pharma companies have formed their subsidiary and a large majority of new drugs launched in India were via this route. This...
Pfizer recalls three anti-bacterial injections in India manufactured by Astral SteriTechThe company was informed by its contract manufacturer in India, Astral, that it has observed an out-of-specification during a routine envir...
Pfizer suspends sale & use of some popular products in India due to technical issuesIn a letter written to stockists, distributors and hospitals across India, Pfizer has asked for temporary suspension of sale and distributi...
Long term investing: 6 midcap stocks with high ROE & consistent ROCENothing wrong in getting excited about Nifty moving up, but before one buys they should be clear what they are buying and why they are buyi...
Long-term wealth creators: 6 midcaps with high ROE & net profit marginAs the Nifty stays in a volatile yet range-bound mode, besides fear of further correction, many investors, especially the ones sitting on c...
High ROE & net profit margin, 4 stocks with two key elements of long term wealth creatorsThere are some businesses which require a constant dose of capital and banking is one of them. There are some which may require a higher am...
Fifteen stocks in focus on Wednesday, 22 March 2017State-owned United Bank of India has set Rs 24.44 as the floor price for its Rs 1,500 crore QIP programme.
Wockhardt gets USFDA nod for generic anti-bacterial drugThe application for the product to the US Food and Drug Administration (USFDA) was made by the company's subsidiary Wockhardt Bio AG, the M...
- 3 cos sue Wyeth over Zosyn patent
Three generic pharmaceutical companies, including one from India, have taken legal action against US pharma major Wyeth.